[{"orgOrder":0,"company":"Eyestem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"iPSC-derived Therapy","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Eyestem \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eyestem \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Eyestem

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Eyecyte RPE, is a lost or damaged retinal pigment epithelium cells replacement therapy is being investigated for the treatment geographic atrophy arising from dry age-related macular degeneration

                          Brand Name : Eyecyte-RPE

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          April 02, 2024

                          Lead Product(s) : iPSC-derived Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank